

Analgesic and NSAID-induced Kidney Disease

Edited by

J. H. STEWART

*Associate Dean, Western Clinical School
University of Sydney, Australia*

Oxford New York Tokyo Melbourne
OXFORD UNIVERSITY PRESS

1993

CONTENTS

| | |
|---|-----|
| List of contributors | xvi |
| 1 Historical introduction | 1 |
| 'Phenacetin nephritis' in Switzerland | 1 |
| Renal papillary necrosis in Scandinavia and Australia | 2 |
| The association with urothelial cancer | 2 |
| The pathology of analgesic nephropathy | 3 |
| The aetiology of analgesic nephropathy | 3 |
| Unanswered questions | 4 |
| 2 The biochemistry and pharmacology of antipyretic-analgesics | 5 |
| Aspirin and salicylate | 5 |
| Chemistry | 5 |
| Pharmacokinetics | 6 |
| Mode of action | 8 |
| Toxicity | 9 |
| Paracetamol (acetaminophen) | 9 |
| Pharmacokinetics | 10 |
| Mechanism of action and pharmacological properties | 12 |
| Toxicity | 12 |
| Phenacetin | 13 |
| Pharmacokinetics | 13 |
| Action | 14 |
| Toxicity | 14 |
| Pyrazolons | 15 |
| Pharmacology | 15 |
| Conclusions | 16 |
| 3 Experimental evidence for nephrotoxicity of analgesics | 17 |
| Summary of experimental results | 17 |
| Phenacetin | 17 |
| Paracetamol | 19 |
| Aspirin | 22 |

| | |
|--|----|
| Caffeine | 23 |
| Pyrazolon derivatives | 23 |
| Indomethacin | 24 |
| Fenemates | 24 |
| Propionic acid derivatives | 24 |
| Mixed analgesics | 24 |
| Causation of renal papillary necrosis | 26 |
| Countercurrent concentration | 26 |
| Medullary ischaemia | 27 |
| Disturbed arachidonic acid and prostaglandin metabolism | 27 |
| Metabolic activation and changes in intermediary metabolism | 27 |
| Pathogenesis of experimental renal papillary necrosis and chronic interstitial nephritis | 29 |
| The aetiological agent | 30 |
| 4 The implication of analgesics in human kidney disease | 32 |
| Quantification of the problem | 33 |
| Prevalence of analgesic nephropathy | 33 |
| Geographical variation in the prevalence of analgesic nephropathy | 36 |
| Is the prevalence of analgesic nephropathy underestimated? | 36 |
| The relation between analgesic abuse and kidney disease | 38 |
| Clinical observations | 38 |
| Epidemiological studies | 38 |
| Nephrotoxicity of different kinds of analgesics | 42 |
| Phenacetin misconception | 42 |
| The nephrotoxicity of single analgesics | 42 |
| The nephrotoxicity of analgesic mixtures | 43 |
| Effects of legislative measures | 45 |
| Conclusion | 46 |
| 5 The abuse of non-narcotic analgesics | 48 |
| Symptomatology and aetiology of the abuse of non-narcotic analgesics | 48 |
| Reasons given for analgesic consumption | 48 |
| Psychosomatic basis for analgesic abuse | 50 |
| The onset of drug habituation | 51 |
| Drug withdrawal | 51 |

| | |
|--|----|
| Psychological aspects of drug use patterns | 52 |
| Do consumers differ from non-consumers with regard to personality? | 53 |
| Do groups of consumers with varying patterns of use differ? | 55 |
| Treatment and prevention | 57 |
| 6 The analgesic syndrome | 58 |
| Caffeine | 60 |
| Withdrawal headache | 60 |
| Direct caffeine toxicity | 60 |
| Codeine | 61 |
| Aspirin and salicylates | 61 |
| Gastric ulcer | 61 |
| Bleeding tendency | 63 |
| Perinatal morbidity and mortality | 63 |
| Phenacetin and paracetamol | 64 |
| Cyanosis, haemolysis, and splenomegaly | 64 |
| Pigmentation | 64 |
| Pyrazolon derivatives | 64 |
| Disorders of mixed or uncertain aetiology | 64 |
| Central nervous system toxicity | 64 |
| Accelerated atherogenesis | 65 |
| Premature ageing | 65 |
| A typical analgesic habitué | 65 |
| 7 The pathology of analgesic nephropathy | 67 |
| The lesions of analgesic-induced renal disease | 67 |
| Capillary sclerosis | 67 |
| Development of papillary necrosis | 68 |
| The relationship of cortical change to papillary necrosis | 74 |
| Fully developed analgesic nephropathy | 77 |
| Pathogenesis of analgesic-induced lesions | 79 |
| Specificity of the analgesic-induced lesion | 80 |
| Complications of analgesic nephropathy | 81 |
| Hypertension | 81 |
| Pyelonephritis | 81 |
| Obstruction | 82 |
| Cysts | 82 |
| Urothelioma | 82 |

| | |
|---|-----|
| Correlation between clinical presentation and morphology | 82 |
| Cessation of analgesic abuse | 83 |
| Concluding remarks | 85 |
| 8 The diagnosis of analgesic nephropathy by organ imaging | 86 |
| Morphological features of analgesic nephropathy | 86 |
| Early signs | 86 |
| Partial papillary necrosis | 86 |
| Total papillary necrosis | 88 |
| Necrosis <i>in situ</i> | 88 |
| The outcome of papillary sloughing | 89 |
| Parenchymal changes in analgesic nephropathy | 89 |
| Transitional cell carcinoma | 89 |
| Imaging techniques | 94 |
| Pyelography | 94 |
| Ultrasonography | 95 |
| Computed tomography and plain film radiology | 96 |
| Differential diagnosis | 96 |
| Normal kidney | 98 |
| Calyceal cysts | 98 |
| Reflux nephropathy (chronic pyelonephritis) | 98 |
| Medullary sponge kidney | 99 |
| Hydronephrotic atrophy | 101 |
| Tuberculosis | 101 |
| Metabolic nephrocalcinosis | 101 |
| 9 Functional defects in analgesic nephropathy | 102 |
| Urinary abnormalities | 102 |
| Microscopy | 102 |
| Proteinuria | 102 |
| Acute urinary response to analgesic ingestion | 103 |
| Renal dysfunction | 103 |
| Glomerular filtration rate | 103 |
| Tubular dysfunction | 103 |
| Consequences of renal impairment | 106 |
| Hyperuricaemia | 106 |
| Hypertension | 106 |
| Renal osteodystrophy | 107 |
| Effect of cessation of analgesic abuse | 107 |

| | | |
|----|--|-----|
| 10 | Clinical presentations of analgesic nephropathy | 108 |
| | Approach to the evaluation of patients | 108 |
| | Drug history | 108 |
| | Clinical examination | 110 |
| | Specific diagnosis of analgesic nephropathy | 111 |
| | Major clinical presentations | 111 |
| | Renal insufficiency | 111 |
| | Abnormal urinary findings | 113 |
| | Hypertension | 113 |
| | Papillary necrosis and calculus formation | 114 |
| | Urinary obstruction | 114 |
| | The value of renal biopsy | 115 |
| | Renal transplant failure | 115 |
| | Analgesic intake in patients with intrinsic renal disease | 116 |
| | Summary | 117 |
| 11 | Treatment of renal failure due to analgesics | 119 |
| | Prevention of further abuse | 119 |
| | Progression of analgesic nephropathy | 121 |
| | Discontinuation of analgesic intake | 121 |
| | Glomerulosclerosis | 121 |
| | Renal artery stenosis | 121 |
| | Acute renal failure | 122 |
| | Management of complications | 123 |
| | Urinary tract infections | 123 |
| | Salt-losing nephropathy | 123 |
| | Renal osteodystrophy | 123 |
| | Arterial hypertension | 125 |
| | Accelerated atherogenesis | 125 |
| | Anaemia | 126 |
| | Carcinoma | 126 |
| | Haemodialysis | 127 |
| | Acceptance for maintenance dialysis | 127 |
| | Renal transplantation | 129 |
| | Summary | 131 |
| 12 | Biochemistry and pharmacology of non-steroidal anti-inflammatory drugs and renal prostaglandins | 133 |
| | Biochemistry and distribution of renal eicosanoids | 135 |

| | |
|---|-----|
| Release of arachidonic acid | 135 |
| Oxidation of arachidonic acid | 135 |
| Degradation and elimination of eicosanoids | 136 |
| Renal distribution of eicosanoids | 136 |
| Synthesis and physiology of glomerular eicosanoids | 137 |
| Synthesis | 137 |
| Vasomotor action of glomerular eicosanoids | 138 |
| Modification of inflammatory responses by glomerular eicosanoids | 139 |
| Synthesis and physiology of tubular eicosanoids | 139 |
| Synthesis | 139 |
| Functions | 139 |
| Effects of local inhibition of cyclooxygenase | 141 |
| Inactivation of renal cyclooxygenase | 142 |
| Differential inhibition of human cyclooxygenase | 143 |
| Low dose aspirin | 144 |
| Sulindac | 144 |
| Tissue specific activities of non-steroidal anti-inflammatory drugs | 145 |
| Conclusions | 146 |
| 13 Effects of non-steroidal anti-inflammatory drugs on renal function | 147 |
| Prostaglandins in the kidney | 147 |
| Modulatory role | 147 |
| Processes regulated by basal levels of prostaglandins | 148 |
| States associated with increased renal prostaglandin synthesis | 148 |
| The effect of prostaglandins on renal function | 148 |
| Renal haemodynamics | 148 |
| Glomerular function | 149 |
| Tubular processes | 150 |
| Endocrine effects | 150 |
| Renal effects of non-steroidal anti-inflammatory drugs | 151 |
| Normal individuals | 151 |
| Disease states | 152 |
| Special populations | 154 |
| Clinical syndromes resulting from non-steroidal anti-inflammatory drugs | 154 |
| Potassium, sodium, and water retention | 156 |
| Intrinsic kidney disease | 156 |

| | |
|---|-----|
| Renal sparing non-steroidal anti-inflammatory drugs | 156 |
| Sulindac | 157 |
| Salicylates | 157 |
| Beneficial renal effects of non-steroidal anti-inflammatory drugs | 158 |
| Long term renal effects of non-steroidal anti-inflammatory drugs | 158 |
| Summary | 159 |
| Acknowledgements | 159 |
| 14 Diseases of the kidney caused by non-steroidal anti-inflammatory drugs | 160 |
| Incidence | 160 |
| Acute interstitial nephritis | 161 |
| Drugs involved | 161 |
| Clinical features | 164 |
| Pathology | 166 |
| Diagnosis | 166 |
| Pathogenesis | 167 |
| Treatment | 167 |
| Acute tubular necrosis | 168 |
| Minimal change nephrotic syndrome | 169 |
| Other glomerulopathies | 170 |
| Membranous nephropathy | 170 |
| Proliferative glomerulonephritis | 170 |
| Papillary necrosis and chronic renal failure | 171 |
| Other lesions | 171 |
| Tubular obstruction | 172 |
| Conclusions | 172 |
| 15 Paracetamol-induced renal tubular cell necrosis | 174 |
| Experimental evidence | 174 |
| Histological findings in experimental animals | 175 |
| Clinical observations | 175 |
| Nephrotoxicity with no or little liver damage | 176 |
| Clinical presentation | 176 |
| Histological findings in patients | 177 |
| Summary | 179 |
| 16 Experimental evidence and the biochemical basis for the role of analgesics in cancer | 180 |
| Urothelial tumours—induction and initiation | 180 |

| | |
|--|-----|
| The aetiological role of analgesic abuse | 181 |
| Phenacetin—an aetiological red herring | 181 |
| Analgesics as carcinogens | 183 |
| Experimental models of renal papillary necrosis | 184 |
| Papillotoxin-induced histochemical changes in renal papillae | 186 |
| The probable mechanism of renal papillary necrosis | 188 |
| Urothelial hyperplasia following renal papillary necrosis | 188 |
| Experimental models of upper urothelial carcinoma | 190 |
| Spontaneous urothelial carcinoma | 191 |
| One-stage models of upper urothelial carcinogenesis | 191 |
| Two-stage models of upper urothelial carcinogenesis | 192 |
| The relationship between renal papillary necrosis and upper urothelial cancer in man | 194 |
| Acknowledgements | 196 |
| 17 Analgesics as human carcinogens—clinical and epidemiological evidence | 197 |
| Case series | 197 |
| Formal epidemiological evidence | 200 |
| Case-control studies | 200 |
| Cohort studies | 200 |
| Summary of evidence implicating phenacetin or other analgesic drugs | 201 |
| Evidence implicating renal papillary necrosis | 205 |
| Population attributable risks | 207 |
| Incidence of renal pelvic cancer | 207 |
| Summary | 210 |
| 18 Carcinoma of the renal pelvis | 211 |
| Pathology | 211 |
| Incidence | 211 |
| Clinical aspects | 212 |
| Diagnosis | 213 |
| Treatment | 214 |
| Prognosis | 215 |
| 19 Prevention of analgesic-induced kidney disease | 216 |
| The aetiology of analgesic-induced kidney disease | 216 |

Contents

xv

| | |
|---|-----|
| The conclusion based on epidemiological evidence | 217 |
| The conclusion based on laboratory evidence | 218 |
| Strategies for prevention | 218 |
| Prohibition of phenacetin (and paracetamol) | 218 |
| Restrictions on marketing compound analgesic preparations | 219 |
| Education and lobbying | 219 |
| Forces promoting continuance of analgesic consumption | 220 |
| The reality | 221 |
| Prevention of secondary renal damage | 221 |
| References | 223 |
| Index | 285 |